title: [Intravenous drug users serologic control: what may be prevented?].
abstract: OBJECTIVE
  To report of IDU serologic control done in 1997 in comparison with another of 1990, in a Health-Care Area of Madrid, Spain, focussing to hepatitis B virus prevention.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  Fuenlabrada-Leganés, 400,000 inhabitants Health-Care Area in the Southeast of Madrid.
  
  
  METHODS
  233 IDU submitted for serological study during 1997 (mean age, 29.5; standard deviation, 6.8; 85.8% males).
  
  
  METHODS
  HIV, HBV, HCV and Treponema pallidum; serological markers were done at Severo Ochoa Hospital and a search for previous reports since 1991. Study of HBV previous vaccination was done with HBsAb marker in HBV seronegative patients.
  
  
  RESULTS
  Prevalence: HBV 39.5% (IC = 33.2-46.1), HCV 49.3% (IC = 42.8-55.9), HIV 11.1% (IC = 7.5-16.1), syphilis 3.4% (IC = 1.5-7). Statistically meaning falls in rates were detected comparing them with results from 1990 (HBV: 67.5%; HCV: 75.1%; HIV: 50.1%; n = 261; p < 0.001). Only 5 (3.55%) out of 141 HBV seronegative patients showed HBsAb titres above 10 mU/I, although 55 (39%) of them had been tested for HBV previously. Nineteen (20.6%) out of 92 patients with HBV markers had previous seronegative reports and 3 of them suffered an acute viral infection.
  
  
  CONCLUSIONS
  We have seen a statistically meaning fall in seroprevalence of the studied agents although a low HBV vaccination rate was achieved.
authors.affiliation: Servicio de Microbiología, Hospital Severo Ochoa, Leganés, Madrid.
authors.forename: A
authors.initials: A
authors.lastname: Delgado-Iribarren
authors.forename: M
authors.initials: M
authors.lastname: Calvo
authors.forename: A
authors.initials: A
authors.lastname: Pérez
authors.forename: M
authors.initials: M
authors.lastname: del Alamo
authors.forename: S
authors.initials: S
authors.lastname: Cercenado
mesh_terms: D000328:Adult; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000453:epidemiology; D006509:Hepatitis B / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D017325:Hepatitis B Vaccines; D006526:Hepatitis C / Q000453:epidemiology; D006801:Humans; D008297:Male; D016036:Seroepidemiologic Studies; D013030:Spain / Q000453:epidemiology; D015819:Substance Abuse, Intravenous / Q000821:virology
chemical_list: D017325:Hepatitis B Vaccines